Literature DB >> 23640307

Over-expression of small ubiquitin-related modifier-1 and sumoylated p53 in colon cancer.

Hongjie Zhang1, Xiaoyi Kuai, Zeyu Ji, Zhengyang Li, Ruihua Shi.   

Abstract

Here we investigated whether the cellular accumulation of p53 protein caused by over-expression of small ubiquitin-related modifier-1 (SUMO-1) could be used as a predictive marker for prognosis in colon cancer. We detected SUMO-1 and p53 protein levels in 46 cases of colon cancer and adjacent tissues by immunohistochemistry and found that SUMO-1 was expressed at much higher levels in colon cancer compared with that in normal colon tissue. Immunoprecipitation and Western blot analysis revealed that the tumor suppressor p53 was present predominantly in the sumoylated rather than the non-sumoylated form in the colon cancer cell lines. A small interfering RNA targeted to SUMO-1 mRNA sequences was used to observe the levels of the p53 protein. Patients who showed high dual expressions of SUMO-1 and p53 tended to experience metastasis more frequently. These results suggest that the cellular accumulation of p53 protein caused by over-expression of SUMO-1 may be involved in tumor aggressiveness. Multivariate analysis confirmed that the high dual expression of SUMO-1 and p53 was an independent factor for evaluating prognosis. SUMO-1 may be useful as a novel target for therapy in colon cancer as well as a clinical indicator for tumor aggressiveness.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23640307     DOI: 10.1007/s12013-013-9612-x

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.194


  16 in total

Review 1.  SUMO and the robustness of cancer.

Authors:  Jacob-Sebastian Seeler; Anne Dejean
Journal:  Nat Rev Cancer       Date:  2017-01-30       Impact factor: 60.716

Review 2.  P53 mutations in colorectal cancer - molecular pathogenesis and pharmacological reactivation.

Authors:  Xiao-Lan Li; Jianbiao Zhou; Zhi-Rong Chen; Wee-Joo Chng
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

Review 3.  Sumoylation in Physiology, Pathology and Therapy.

Authors:  Umut Sahin; Hugues de Thé; Valérie Lallemand-Breitenbach
Journal:  Cells       Date:  2022-02-26       Impact factor: 6.600

4.  Ubiquitination and degradation of SUMO1 by small-molecule degraders extends survival of mice with patient-derived tumors.

Authors:  Anita C Bellail; Hong Ri Jin; Ho-Yin Lo; Sung Han Jung; Chafiq Hamdouchi; Daeho Kim; Ryan K Higgins; Maximilian Blanck; Carlos le Sage; Benedict C S Cross; Jing Li; Amber L Mosley; Aruna B Wijeratne; Wen Jiang; Manali Ghosh; Yin Quan Zhao; Paula M Hauck; Anantha Shekhar; Chunhai Hao
Journal:  Sci Transl Med       Date:  2021-10-13       Impact factor: 19.319

5.  Effects of targeting sumoylation processes during latent and induced Epstein-Barr virus infections using the small molecule inhibitor ML-792.

Authors:  Peter Garcia; Abigail Harrod; Shruti Jha; Jessica Jenkins; Alex Barnhill; Holden Lee; Merritt Thompson; Jordan Pringle Williams; James Barefield; Ashton Mckinnon; Persia Suarez; Ananya Shah; Angela J Lowrey; Gretchen L Bentz
Journal:  Antiviral Res       Date:  2021-02-10       Impact factor: 5.970

6.  Identification of c-MYC SUMOylation by mass spectrometry.

Authors:  Manpreet Kalkat; Pak-Kei Chan; Amanda R Wasylishen; Tharan Srikumar; Sam S Kim; Romina Ponzielli; David P Bazett-Jones; Brian Raught; Linda Z Penn
Journal:  PLoS One       Date:  2014-12-18       Impact factor: 3.240

7.  Quantitative mass spectrometry analysis reveals a panel of nine proteins as diagnostic markers for colon adenocarcinomas.

Authors:  Apurva Atak; Samiksha Khurana; Kishore Gollapalli; Panga Jaipal Reddy; Roei Levy; Stav Ben-Salmon; Dror Hollander; Maya Donyo; Anke Heit; Agnes Hotz-Wagenblatt; Hadas Biran; Roded Sharan; Shailendra Rane; Ashutosh Shelar; Gil Ast; Sanjeeva Srivastava
Journal:  Oncotarget       Date:  2018-02-05

8.  The role of sentrin-specific protease 2 substrate recognition in TGF-β-induced tumorigenesis.

Authors:  Che-Chang Chang; Yen-Sung Huang; Ying-Mei Lin; Chia-Ju Lin; Jen-Chong Jeng; Shin-Mei Liu; Tsai-Ling Ho; Ruei-Ting Chang; Chun A Changou; Chun-Chen Ho; Hsiu-Ming Shih
Journal:  Sci Rep       Date:  2018-06-28       Impact factor: 4.379

Review 9.  Current Status of SUMOylation Inhibitors.

Authors:  Christopher M Brackett; Brian S J Blagg
Journal:  Curr Med Chem       Date:  2021       Impact factor: 4.530

Review 10.  SUMOylation-Mediated Regulation of Cell Cycle Progression and Cancer.

Authors:  Karolin Eifler; Alfred C O Vertegaal
Journal:  Trends Biochem Sci       Date:  2015-10-22       Impact factor: 13.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.